Evidence map›Paper›PMID 27397436›Full record

ArticleJournal of applied toxicology : JAT2017

Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage.

Francis S Wolenski, Pooja Shah, Tomoya Sano, Tadahiro Shinozawa, Hugues Bernard, Matt J Gallacher, Shylah D Wyllie, Georgianna Varrone, Lisa A Cicia, Mary E Carsillo and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of applied toxicology : JAT, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron.Toxicological sciences : an official journal of the Society of Toxicology · 2021
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Identification of urinary microRNA biomarkers forJournal of veterinary science · 2020
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. MicroRNAs as biomarkers for liver injury: Current knowledge, challenges and future prospects.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Francis S WolenskiDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Pooja ShahMolecular Pathology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Tomoya SanoDrug Safety Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, 251-8555, Japan.
Tadahiro ShinozawaDrug Safety Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, 251-8555, Japan.
Hugues BernardMolecular Pathology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Matt J GallacherDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Shylah D WyllieDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Georgianna VarroneDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Lisa A CiciaDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Mary E CarsilloDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Craig D FisherDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Sean E OttingerDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Erik KoenigMolecular Pathology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Patrick J KirbyDrug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
Takeda (Japan) · JPMillennium Engineering and Integration (United States) · USTakeda (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNA) are short single-stranded RNA sequences that have a role in the post-transcriptional regulation of genes. The identification of tissue specific or enriched miRNAs has great potential as novel safety biomarkers. One longstanding goal is to associate the increase of miRNA in biofluids (e.g., plasma and urine) with tissue-specific damage. Next-generation sequencing (miR-seq) was used to analyze changes in miRNA profiles of tissue, plasma and urine samples of rats treated with either a nephrotoxicant (cisplatin) or one of two hepatotoxicants (acetaminophen [APAP] or carbon tetrachloride [CCL

Indexed as

Chemical and Drug Induced Liver InjuryKidney DiseasesMicroRNAsAcetaminophenAnimalsBiomarkersCisplatinDisease Models, AnimalKidneyLiverMaleRats, Sprague-DawleyAcetaminophenBiomarkersCisplatinMicroRNAsbioinformaticsbiomarkerhepatotoxicitymicroRNAmiR-seqnephrotoxicity

Identifiers

PMID27397436
PMCPMC5298042
OpenAlexW2474290073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.